Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

Preceptor Perceptions of Team Quality Improvement Projects Conducted With the Educating Pharmacists in Quality Program.

Nelson ML, Dean JL, Hannum C, Warholak T.

Am J Med Qual. 2018 Jul 1:1062860618787774. doi: 10.1177/1062860618787774. [Epub ahead of print] No abstract available.

PMID:
29998739
2.

Influences of Mental Illness, Current Psychological State, and Concussion History on Baseline Concussion Assessment Performance.

Weber ML, Dean JL, Hoffman NL, Broglio SP, McCrea M, McAllister TW, Schmidt JD; CARE Consortium Investigators, Hoy AR, Hazzard JB, Kelly LA, Ortega JD, Port N, Putukian M, Langford TD, Tierney R, Campbell DE, McGinty G, O'Donnell P, Svoboda SJ, DiFiori JP, Giza CC, Benjamin HJ, Buckley T, Kaminski TW, Clugston JR, Feigenbaum LA, Eckner JT, Guskiewicz K, Mihalik JP, Miles JD, Anderson S, Master CL, Collins M, Kontos AP, Bazarian JJ, Chrisman SPD, Brooks A, Duma S, Bullers CT, Miles CM, Dykhuizen BH.

Am J Sports Med. 2018 Jun;46(7):1742-1751. doi: 10.1177/0363546518765145. Epub 2018 Apr 19.

PMID:
29672135
3.

Heat shock protein-27 and sex-selective regulation of muscarinic and proteinase-activated receptor 2-mediated vasodilatation: differential sensitivity to endothelial NOS inhibition.

Pulakazhi Venu VK, Saifeddine M, Mihara K, El-Daly M, Belke D, Dean JLE, O'Brien ER, Hirota SA, Hollenberg MD.

Br J Pharmacol. 2018 Jun;175(11):2063-2076. doi: 10.1111/bph.14200. Epub 2018 Apr 25.

PMID:
29532457
4.

Tryptophan-Mediated Interactions between Tristetraprolin and the CNOT9 Subunit Are Required for CCR4-NOT Deadenylase Complex Recruitment.

Bulbrook D, Brazier H, Mahajan P, Kliszczak M, Fedorov O, Marchese FP, Aubareda A, Chalk R, Picaud S, Strain-Damerell C, Filippakopoulos P, Gileadi O, Clark AR, Yue WW, Burgess-Brown NA, Dean JLE.

J Mol Biol. 2018 Mar 2;430(5):722-736. doi: 10.1016/j.jmb.2017.12.018. Epub 2017 Dec 29.

PMID:
29291391
5.

Gain-of-Function Mutation of Tristetraprolin Impairs Negative Feedback Control of Macrophages In Vitro yet Has Overwhelmingly Anti-Inflammatory Consequences In Vivo.

O'Neil JD, Ross EA, Ridley ML, Ding Q, Tang T, Rosner DR, Crowley T, Malhi D, Dean JL, Smallie T, Buckley CD, Clark AR.

Mol Cell Biol. 2017 May 16;37(11). pii: e00536-16. doi: 10.1128/MCB.00536-16. Print 2017 Jun 1.

6.
7.

RB Loss Promotes Prostate Cancer Metastasis.

Thangavel C, Boopathi E, Liu Y, Haber A, Ertel A, Bhardwaj A, Addya S, Williams N, Ciment SJ, Cotzia P, Dean JL, Snook A, McNair C, Price M, Hernandez JR, Zhao SG, Birbe R, McCarthy JB, Turley EA, Pienta KJ, Feng FY, Dicker AP, Knudsen KE, Den RB.

Cancer Res. 2017 Feb 15;77(4):982-995. doi: 10.1158/0008-5472.CAN-16-1589. Epub 2016 Dec 6.

8.
9.

Treatment of inflammatory arthritis via targeting of tristetraprolin, a master regulator of pro-inflammatory gene expression.

Ross EA, Naylor AJ, O'Neil JD, Crowley T, Ridley ML, Crowe J, Smallie T, Tang TJ, Turner JD, Norling LV, Dominguez S, Perlman H, Verrills NM, Kollias G, Vitek MP, Filer A, Buckley CD, Dean JL, Clark AR.

Ann Rheum Dis. 2017 Mar;76(3):612-619. doi: 10.1136/annrheumdis-2016-209424. Epub 2016 Sep 5.

10.

Neutrophil-derived alpha defensins control inflammation by inhibiting macrophage mRNA translation.

Brook M, Tomlinson GH, Miles K, Smith RW, Rossi AG, Hiemstra PS, van 't Wout EF, Dean JL, Gray NK, Lu W, Gray M.

Proc Natl Acad Sci U S A. 2016 Apr 19;113(16):4350-5. doi: 10.1073/pnas.1601831113. Epub 2016 Apr 4.

11.

Performance of a microscope with an embedded oscillating pinned-contact liquid lens.

Dean JL, Hirsa AH.

Appl Opt. 2015 Sep 20;54(27):8228-34. doi: 10.1364/AO.54.008228.

PMID:
26406529
12.

DNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression and Metastasis.

Goodwin JF, Kothari V, Drake JM, Zhao S, Dylgjeri E, Dean JL, Schiewer MJ, McNair C, Jones JK, Aytes A, Magee MS, Snook AE, Zhu Z, Den RB, Birbe RC, Gomella LG, Graham NA, Vashisht AA, Wohlschlegel JA, Graeber TG, Karnes RJ, Takhar M, Davicioni E, Tomlins SA, Abate-Shen C, Sharifi N, Witte ON, Feng FY, Knudsen KE.

Cancer Cell. 2015 Jul 13;28(1):97-113. doi: 10.1016/j.ccell.2015.06.004.

13.

Dual-Specificity Phosphatase 1 and Tristetraprolin Cooperate To Regulate Macrophage Responses to Lipopolysaccharide.

Smallie T, Ross EA, Ammit AJ, Cunliffe HE, Tang T, Rosner DR, Ridley ML, Buckley CD, Saklatvala J, Dean JL, Clark AR.

J Immunol. 2015 Jul 1;195(1):277-88. doi: 10.4049/jimmunol.1402830. Epub 2015 May 27.

14.

Dominant Suppression of Inflammation via Targeted Mutation of the mRNA Destabilizing Protein Tristetraprolin.

Ross EA, Smallie T, Ding Q, O'Neil JD, Cunliffe HE, Tang T, Rosner DR, Klevernic I, Morrice NA, Monaco C, Cunningham AF, Buckley CD, Saklatvala J, Dean JL, Clark AR.

J Immunol. 2015 Jul 1;195(1):265-76. doi: 10.4049/jimmunol.1402826. Epub 2015 May 22.

15.

Consequence of the tumor-associated conversion to cyclin D1b.

Augello MA, Berman-Booty LD, Carr R 3rd, Yoshida A, Dean JL, Schiewer MJ, Feng FY, Tomlins SA, Gao E, Koch WJ, Benovic JL, Diehl JA, Knudsen KE.

EMBO Mol Med. 2015 May;7(5):628-47. doi: 10.15252/emmm.201404242.

16.

PARP-14 combines with tristetraprolin in the selective posttranscriptional control of macrophage tissue factor expression.

Iqbal MB, Johns M, Cao J, Liu Y, Yu SC, Hyde GD, Laffan MA, Marchese FP, Cho SH, Clark AR, Gavins FN, Woollard KJ, Blackshear PJ, Mackman N, Dean JL, Boothby M, Haskard DO.

Blood. 2014 Dec 4;124(24):3646-55. doi: 10.1182/blood-2014-07-588046. Epub 2014 Oct 7.

17.

Selective tumor necrosis factor receptor I blockade is antiinflammatory and reveals immunoregulatory role of tumor necrosis factor receptor II in collagen-induced arthritis.

McCann FE, Perocheau DP, Ruspi G, Blazek K, Davies ML, Feldmann M, Dean JL, Stoop AA, Williams RO.

Arthritis Rheumatol. 2014 Oct;66(10):2728-38. doi: 10.1002/art.38755.

18.

Evaluation of an educational program on deciphering heterogeneity for medical coverage decisions.

Warholak TL, Hilgaertner JW, Dean JL, Taylor AM, Hines LE, Hurwitz J, Brown M, Malone DC.

J Manag Care Spec Pharm. 2014 Jun;20(6):566-73.

19.

TNFR2 increases the sensitivity of ligand-induced activation of the p38 MAPK and NF-κB pathways and signals TRAF2 protein degradation in macrophages.

Ruspi G, Schmidt EM, McCann F, Feldmann M, Williams RO, Stoop AA, Dean JL.

Cell Signal. 2014 Apr;26(4):683-90. doi: 10.1016/j.cellsig.2013.12.009. Epub 2013 Dec 27.

PMID:
24378531
20.

USP22 regulates oncogenic signaling pathways to drive lethal cancer progression.

Schrecengost RS, Dean JL, Goodwin JF, Schiewer MJ, Urban MW, Stanek TJ, Sussman RT, Hicks JL, Birbe RC, Draganova-Tacheva RA, Visakorpi T, DeMarzo AM, McMahon SB, Knudsen KE.

Cancer Res. 2014 Jan 1;74(1):272-86. doi: 10.1158/0008-5472.CAN-13-1954. Epub 2013 Nov 6.

21.

Heat shock protein B1-deficient mice display impaired wound healing.

Crowe J, Aubareda A, McNamee K, Przybycien PM, Lu X, Williams RO, Bou-Gharios G, Saklatvala J, Dean JL.

PLoS One. 2013 Oct 15;8(10):e77383. doi: 10.1371/journal.pone.0077383. eCollection 2013.

22.

A hormone-DNA repair circuit governs the response to genotoxic insult.

Goodwin JF, Schiewer MJ, Dean JL, Schrecengost RS, de Leeuw R, Han S, Ma T, Den RB, Dicker AP, Feng FY, Knudsen KE.

Cancer Discov. 2013 Nov;3(11):1254-71. doi: 10.1158/2159-8290.CD-13-0108. Epub 2013 Sep 11.

23.

Cross talk between the Akt and p38α pathways in macrophages downstream of Toll-like receptor signaling.

McGuire VA, Gray A, Monk CE, Santos SG, Lee K, Aubareda A, Crowe J, Ronkina N, Schwermann J, Batty IH, Leslie NR, Dean JL, O'Keefe SJ, Boothby M, Gaestel M, Arthur JS.

Mol Cell Biol. 2013 Nov;33(21):4152-65. doi: 10.1128/MCB.01691-12. Epub 2013 Aug 26.

24.

Cezanne regulates inflammatory responses to hypoxia in endothelial cells by targeting TRAF6 for deubiquitination.

Luong le A, Fragiadaki M, Smith J, Boyle J, Lutz J, Dean JL, Harten S, Ashcroft M, Walmsley SR, Haskard DO, Maxwell PH, Walczak H, Pusey C, Evans PC.

Circ Res. 2013 Jun 7;112(12):1583-91. doi: 10.1161/CIRCRESAHA.111.300119. Epub 2013 Apr 5.

PMID:
23564640
25.

The role of tumor suppressor dysregulation in prostate cancer progression.

Dean JL, Knudsen KE.

Curr Drug Targets. 2013 Apr;14(4):460-71. Review.

PMID:
23410128
26.

MSK1 and MSK2 inhibit lipopolysaccharide-induced prostaglandin production via an interleukin-10 feedback loop.

MacKenzie KF, Van Den Bosch MW, Naqvi S, Elcombe SE, McGuire VA, Reith AD, Blackshear PJ, Dean JL, Arthur JS.

Mol Cell Biol. 2013 Apr;33(7):1456-67. doi: 10.1128/MCB.01690-12. Epub 2013 Feb 4.

27.

Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes.

Augello MA, Burd CJ, Birbe R, McNair C, Ertel A, Magee MS, Frigo DE, Wilder-Romans K, Shilkrut M, Han S, Jernigan DL, Dean JL, Fatatis A, McDonnell DP, Visakorpi T, Feng FY, Knudsen KE.

J Clin Invest. 2013 Jan;123(1):493-508. doi: 10.1172/JCI64750. Epub 2012 Dec 21.

28.

The p38 MAPK Pathway in Rheumatoid Arthritis: A Sideways Look.

Clark AR, Dean JL.

Open Rheumatol J. 2012;6:209-19. doi: 10.2174/1874312901206010209. Epub 2012 Sep 7.

29.

Dual roles of PARP-1 promote cancer growth and progression.

Schiewer MJ, Goodwin JF, Han S, Brenner JC, Augello MA, Dean JL, Liu F, Planck JL, Ravindranathan P, Chinnaiyan AM, McCue P, Gomella LG, Raj GV, Dicker AP, Brody JR, Pascal JM, Centenera MM, Butler LM, Tilley WD, Feng FY, Knudsen KE.

Cancer Discov. 2012 Dec;2(12):1134-49. doi: 10.1158/2159-8290.CD-12-0120. Epub 2012 Sep 19.

30.

Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors.

Dean JL, McClendon AK, Hickey TE, Butler LM, Tilley WD, Witkiewicz AK, Knudsen ES.

Cell Cycle. 2012 Jul 15;11(14):2756-61. doi: 10.4161/cc.21195. Epub 2012 Jul 15.

31.

CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy.

McClendon AK, Dean JL, Rivadeneira DB, Yu JE, Reed CA, Gao E, Farber JL, Force T, Koch WJ, Knudsen ES.

Cell Cycle. 2012 Jul 15;11(14):2747-55. doi: 10.4161/cc.21127. Epub 2012 Jul 15.

32.

Modification of the DNA damage response by therapeutic CDK4/6 inhibition.

Dean JL, McClendon AK, Knudsen ES.

J Biol Chem. 2012 Aug 17;287(34):29075-87. doi: 10.1074/jbc.M112.365494. Epub 2012 Jun 25.

33.

RB and p53 cooperate to prevent liver tumorigenesis in response to tissue damage.

McClendon AK, Dean JL, Ertel A, Fu Z, Rivadeneira DB, Reed CA, Bourgo RJ, Witkiewicz A, Addya S, Mayhew CN, Grimes HL, Fortina P, Knudsen ES.

Gastroenterology. 2011 Oct;141(4):1439-50. doi: 10.1053/j.gastro.2011.06.046. Epub 2011 Jun 24.

34.

Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer.

Thangavel C, Dean JL, Ertel A, Knudsen KE, Aldaz CM, Witkiewicz AK, Clarke R, Knudsen ES.

Endocr Relat Cancer. 2011 Apr 28;18(3):333-45. doi: 10.1530/ERC-10-0262. Print 2011 Jun.

35.

RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response.

Ertel A, Dean JL, Rui H, Liu C, Witkiewicz AK, Knudsen KE, Knudsen ES.

Cell Cycle. 2010 Oct 15;9(20):4153-63. Epub 2010 Oct 27.

36.

MAPKAP kinase 2 blocks tristetraprolin-directed mRNA decay by inhibiting CAF1 deadenylase recruitment.

Marchese FP, Aubareda A, Tudor C, Saklatvala J, Clark AR, Dean JL.

J Biol Chem. 2010 Sep 3;285(36):27590-600. doi: 10.1074/jbc.M110.136473. Epub 2010 Jul 1.

37.

Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure.

Dean JL, Thangavel C, McClendon AK, Reed CA, Knudsen ES.

Oncogene. 2010 Jul 15;29(28):4018-32. doi: 10.1038/onc.2010.154. Epub 2010 May 17.

PMID:
20473330
38.

Differential impact of tumor suppressor pathways on DNA damage response and therapy-induced transformation in a mouse primary cell model.

McClendon AK, Dean JL, Ertel A, Knudsen ES.

PLoS One. 2010 Jan 1;5(1):e8558. doi: 10.1371/journal.pone.0008558.

39.

Multimode vibration analysis with high-speed TV holography and a spatiotemporal 3D Fourier transform method.

Trillo C, Doval AF, Mendoza-Santoyo F, Pérez-López C, de la Torre-Ibarra M, Deán JL.

Opt Express. 2009 Sep 28;17(20):18014-25. doi: 10.1364/OE.17.018014.

PMID:
19907591
40.

The p38 MAPK pathway mediates both antiinflammatory and proinflammatory processes: comment on the article by Damjanov and the editorial by Genovese.

Clark AR, Dean JL, Saklatvala J.

Arthritis Rheum. 2009 Nov;60(11):3513-4. doi: 10.1002/art.24919. No abstract available.

41.

Modeling the effect of the RB tumor suppressor on disease progression: dependence on oncogene network and cellular context.

Dean JL, McClendon AK, Stengel KR, Knudsen ES.

Oncogene. 2010 Jan 7;29(1):68-80. doi: 10.1038/onc.2009.313. Epub 2009 Oct 5.

PMID:
19802012
42.

The p38 MAPK pathway inhibits tristetraprolin-directed decay of interleukin-10 and pro-inflammatory mediator mRNAs in murine macrophages.

Tudor C, Marchese FP, Hitti E, Aubareda A, Rawlinson L, Gaestel M, Blackshear PJ, Clark AR, Saklatvala J, Dean JL.

FEBS Lett. 2009 Jun 18;583(12):1933-8. doi: 10.1016/j.febslet.2009.04.039. Epub 2009 May 3.

43.

Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcome.

Millar EK, Dean JL, McNeil CM, O'Toole SA, Henshall SM, Tran T, Lin J, Quong A, Comstock CE, Witkiewicz A, Musgrove EA, Rui H, Lemarchand L, Setiawan VW, Haiman CA, Knudsen KE, Sutherland RL, Knudsen ES.

Oncogene. 2009 Apr 16;28(15):1812-20. doi: 10.1038/onc.2009.13. Epub 2009 Mar 16.

44.

Determination of thickness and elastic constants of aluminum plates from full-field wavelength measurements of single-mode narrowband Lamb waves.

Deán JL, Trillo C, Doval AF, Fernández JL.

J Acoust Soc Am. 2008 Sep;124(3):1477-89. doi: 10.1121/1.2945707.

PMID:
19045639
45.

Cyclin D1b is aberrantly regulated in response to therapeutic challenge and promotes resistance to estrogen antagonists.

Wang Y, Dean JL, Millar EK, Tran TH, McNeil CM, Burd CJ, Henshall SM, Utama FE, Witkiewicz A, Rui H, Sutherland RL, Knudsen KE, Knudsen ES.

Cancer Res. 2008 Jul 15;68(14):5628-38. doi: 10.1158/0008-5472.CAN-07-3170.

46.

RB status governs differential sensitivity to cytotoxic and molecularly-targeted therapeutic agents.

Stengel KR, Dean JL, Seeley SL, Mayhew CN, Knudsen ES.

Cell Cycle. 2008 Apr 15;7(8):1095-103. Epub 2008 Feb 11.

PMID:
18414045
47.

A semi-structured interview to assess visual hallucinations in older people.

Mosimann UP, Collerton D, Dudley R, Meyer TD, Graham G, Dean JL, Bearn D, Killen A, Dickinson L, Clarke MP, McKeith IG.

Int J Geriatr Psychiatry. 2008 Jul;23(7):712-8. doi: 10.1002/gps.1965.

PMID:
18181237
48.

NF-kappaB suppression by the deubiquitinating enzyme Cezanne: a novel negative feedback loop in pro-inflammatory signaling.

Enesa K, Zakkar M, Chaudhury H, Luong le A, Rawlinson L, Mason JC, Haskard DO, Dean JL, Evans PC.

J Biol Chem. 2008 Mar 14;283(11):7036-45. doi: 10.1074/jbc.M708690200. Epub 2008 Jan 4.

49.

Heat shock protein 27 functions in inflammatory gene expression and transforming growth factor-beta-activated kinase-1 (TAK1)-mediated signaling.

Alford KA, Glennie S, Turrell BR, Rawlinson L, Saklatvala J, Dean JL.

J Biol Chem. 2007 Mar 2;282(9):6232-41. Epub 2007 Jan 3.

50.

Subjective memory complaints, white-matter lesions, depressive symptoms, and cognition in elderly patients.

Minett TS, Dean JL, Firbank M, English P, O'Brien JT.

Am J Geriatr Psychiatry. 2005 Aug;13(8):665-71.

PMID:
16085782

Supplemental Content

Support Center